The effect of Intravenous immunoglobulin on COVID-19 infection

Effect of Intravenous immunoglobulin (IVIG) versus Kaletra (lopinavir and ritonavir) tablets in patients with acute respiratory infection (COVID-19): A clinical trial studies

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20200418047116N1

Enrollment

Registered

2020-05-04

Start date

2020-03-10

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COVID-19 disease. COVID-19

Interventions

Intervention 1: Intervention group: intravenous immunoglobulin (IVIG), brand name Intratect ®, 400 mg/kg/day in 3 doses will be administered by slow intravenous infusion. Intervention 2: Control grou

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: Positive PCR for COVID -19 Informed consent for inclusion Hypoxemia not responsive to oxygen therapy Loss of consciousness (GCS<=14) Hemodynamic instability Hypercapnia Extent of pulmonary involvement Non-use estrogen-containing compounds Non-be pregnant or breastfeeding

Exclusion criteria

Exclusion criteria: Sensitivity to IVIG IgA deficiency history Allergic reaction during IVIG injection

Design outcomes

Primary

Measure	Time frame
Pulmonary manifestations. Timepoint: before and after treatment. Method of measurement: Computed Tomography scan.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNegar Shafaei Bajestani

Gonabad University of Medical Sciences

Shafaei.n@gmu.ac.ir+98 51 5723 6833

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026